Background:
Hyperprolactinemia can lead to weight gain, insulin resistance, abnormal
glucose homeostasis and dyslipidemia. Reversibility of these changes after normalization of prolactin
with dopamine agonists is still controversial and needs more clarification.
Objective:
We aimed to: 1) evaluate and compare metabolic and anthropometric profile in female with
newly diagnosed prolactin-secreting adenoma versus female idiopathic hyperprolactinemic patients;
2) compare the effects of one year cabergoline therapy on the metabolic profile and anthropometric
parameters (by using visceral adiposity index as index for evaluation of adipose tissue dysfunction) in
females with prolactinoma to female idiopathic hyperprolactinemic patients.
Patients and Methods:
We enrolled 40 female patients with newly diagnosed prolactinoma and 40
female patients with idiopathic hyperprolactinemia, who were matched according to: age; weight;
BMI; waist; and prolactin levels. We enrolled the participants in this study at the time of diagnosis
before therapy and they were followed up for 12 months.
Results:
Cabergoline therapy had significant favorable effects on metabolic and anthropometric parameters,
visceral adiposity index and in all patients (apart from HDLc in prolactinoma patients).
:
Cabergoline therapy was significantly more effective in patient with idiopathic hyperprolactinemia
than prolactinoma patients with regard to BMI, waist circumference, HDLc and visceral adiposity index
despite normalization of prolactin levels in both groups.
Conclusion:
12 months of Cabergoline treatment improved most of the anthropometric and metabolic
parameters, and visceral adiposity index as a marker for adipose tissue dysfunction in both idiopathic
hyperprolactinemia and prolactinoma patients. However, Cabergoline treatment was more effective in
idiopathic hyperprolactinemic than prolactinoma patients.
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients
